pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
Itacitinib, placebo of itacitinib 100mg
Phase 2 · small molecule · Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening
Itacitinib, placebo of itacitinib 100mg for Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP180613
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening
- Status
- active
- Trials
- 1